Opioid Induced Constipation Treatment Market

Opioids are prescribed to inhibit non-cancerous chronic pains. Apart from reliving the pain, the drug also results in constipation, which is a side effect. Opioid induced cancer is signified by less than three bowel movements in a week. The constipation, further, requires treatment.

As a result, demand for treatment is increasing vibrantly. The constipation is treated using osmotic, stimulants, and softeners.

To keep up with the demand for opioid induced constipation treatment, manufacturing companies are indulging in research and development activities. Advances in pharmaceutical industry and growing investment on research activities are likely to drive growth of opioid induced constipation treatment market in coming years.

Many global companies are focusing towards development of new medicines for treatment of opioid induced constipation. New medicines are being discovered frequently due to increasing incidence of opioid induced constipation. This, in turn, is anticipated to boost opioid induced constipation treatment market at high growth rate.

Apart from opioid induced constipation treatment, the medicine is also used for colon clearing, stool softening, and bowel movement regulation. High demand for the medicine is also a fuelling factor for growth of the global opioid induced constipation treatment market.

Moreover, rising incidence of headaches and spinal pain as a result of sedentary lifestyle have also accelerated the use of opioids for reducing pain. The factor is also likely to drive the opioid induced constipation treatment market in coming years.

Moreover, growing number of population undergoing surgical procedures has scaled use of pain killers. This has resulted in rise of number of patients with opioid induced constipation. This, in turn, is positively impacting growth of opioid induced constipation treatment market.

However, high cost of these drugs may limit their adoption rate. Lack of awareness and unfavourable reimbursement facilities are some of the factors likely to restrain growth of the market in coming years.

Global Opioid Induced Constipation Treatment Market : Overview

Opioid induced constipation (OIC) market has seen new strides on the back of the growing understanding of its etiology and pharmacology. A large numbers of pharmacological of and non-pharmacological therapies have been used in the prevention and management of OIC. Patients with non-cancer pain are at one of the key target populations. The marked prevalence of opioid-induced constipation has been the key driver for the market. While the figures for the prevalence rates vary in various estimates, most indicate that more than half of non-cancer patients worldwide suffer from the condition. Opioids show deleterious GI consequences, have led to constipation, and other related adverse events such as nausea, bloat, vomiting, abdominal pain, and straining, all which lead to poor quality of life in the affected. In the coming years, as more patients are expected to be diagnosed with OIC, the drug pipeline in the opioid induced constipation market will get a solid boost.

The global opioid-induced constipation treatment market stood at US$ 731.2 million in 2016. Clocking a staggeringly high CAGR of 31.2%, the valuation of the market will climb to US$ 4.8 billion by 2023.

Growing Awareness of Opioid-Induced Constipation Medicines Boosting New Agents

On the basis of drug class, the report segments the opioid induced constipation market into mu-opioid receptor antagonist and chloride channel activator. Of the two, the latter currently leads and held the major share in the opioid-induced constipation treatment market. The array of drugs in the segment are increasingly effective in treating the chronic conditions in IOC.         

However, antagonistic mu-opioid recipients are gathering steam in opioid-induced constipation treatment market, with players in the opioid induced constipation market being successful in improving the efficacy. Most of these drug classes are prescription drugs. In the next few years, both these segments are expected to prosper on the back of growing awareness of opioid-induced constipation medicines among clinicians and the patient population. Patients have been benefitting with the growing array of new agents that act helpful as initial therapies in the opioid induced constipation market.

Consumption of Prescription Opioids and Growing Clinical Evidence Spur Demands in North America

The key regional segments in the opioid-induced constipation treatment market comprise North America, Latin America, Asia Pacific, Europe, and the Middle East and South Africa. Of these, North America has contributed substantial revenues over the past few years. The regional market is projected to generate US$4.05 billion of income from opioid constipation treatment. The demand in North America has been widespread, propelled by substantial numbers of people who take opioid therapies. In many cases, the disease in a growing population in the regions is characterized by chronic non-cancer pain. Moreover, the consumption of prescription opioids in the U.S. is boosting the regional market. Further, a growing body of research has generated considerable clinical evidence in the role of various therapies in managing IOC.

This report on the opioid induced constipation treatment market studies the current and future scenario of the global market. Large number of chronic pain sufferers is responsible for rising opioid consumption. Severe chronic constipation is a major side effect of consumption of opioid and shows resistance to traditional laxatives. Hence, novel targeted therapy has been prescribed to treat opioid induced constipation. Rising number of OIC sufferers, launch of targeted medicines, and growing awareness about the therapy are the major drivers of the market. 

The opioid induced constipation treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on the dosage form of the drug, type of drug class, and their geographical analysis. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises regulatory framework for major countries and event impact analysis. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global opioid induced constipation treatment market. 

Based on dosage form of the drug, the market has been segmented into three major forms: solid, semi-solid, and liquid. The market segments have been analyzed based on available approved drugs for treatment and their dosage forms, cost-effectiveness, and preference for dosage form by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. 

Based on drug class, the opioid induced constipation treatment market has been segmented into three major categories based on their mechanism of action: mu opioid receptor antagonist (Movantik and Relistor), chloride channel activator (Amitiza), and others (Resolor and traditional medicines). The market segments have been extensively analyzed based on efficacy, cost, revenue, number of launched drugs, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year. 

Pipeline analysis has also been provided in the report. The market has been estimated for drugs that are in phase III (late stage) clinical trials. Presently, Naldemedine is an under NDA review. A tabular representation has been included for phase II and phase I drugs. 

Geographically, the global opioid induced constipation treatment market has been categorized into five major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, France, and Rest of Europe), Asia Pacific (Australia, Japan, South Korea, and Rest of Asia Pacific), Latin America (Brazil and Rest of Latin America) and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions. 

The report also profiles major players in the global opioid induced constipation treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals. 

The global opioid induced constipation treatment market has been segmented as follows:

  • Global Opioid Induced Constipation Treatment Market Revenue, by Dosage form of Drugs, 2013–2023 (US$ Mn)
    • Solid
    • Semisolid
    • Liquid
  • Global Opioid Induced Constipation Treatment Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
    • mu-opioid receptor antagonist
    • Chloride channel activator
    • Others
  • Global Opioid Induced Constipation Treatment Market Revenue, by Pipeline, 2013-2023 (US$ Mn)
    • Late Stage (phase III) candidates (forecast from the year of approval till 2023) (US$ Mn)
      • Naldemedine
      • Others
    • Early Stage (phase II and phase I) candidates (tabular representation)
      • Axelopran
      • Others
  • Global Opioid Induced Constipation Treatment Market Revenue, By Geography, 2013-2023 (US$ Mn)
    • Overview
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia Pacific
      • Australia
      • Japan
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Rest of the World

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Opioidinduced Constipation Treatment Market

Buy Now